These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 22235941)

  • 1. Safety evaluation of combination toceranib phosphate (Palladia®) and piroxicam in tumour-bearing dogs (excluding mast cell tumours): a phase I dose-finding study.
    Chon E; McCartan L; Kubicek LN; Vail DM
    Vet Comp Oncol; 2012 Sep; 10(3):184-93. PubMed ID: 22235941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety evaluation of combination doxorubicin and toceranib phosphate (Palladia®) in tumour bearing dogs: a phase I dose-finding study.
    Pellin MA; Wouda RM; Robinson K; Tsimbas K; Kurzman ID; Biller BJ; Vail DM
    Vet Comp Oncol; 2017 Sep; 15(3):919-931. PubMed ID: 27146577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary frontal sinus squamous cell carcinoma in three dogs treated with piroxicam combined with carboplatin or toceranib.
    de Vos J; Ramos Vega S; Noorman E; de Vos P
    Vet Comp Oncol; 2012 Sep; 10(3):206-13. PubMed ID: 22236048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety evaluation of combination carboplatin and toceranib phosphate (Palladia) in tumour-bearing dogs: A phase I dose finding study.
    Wouda RM; Hocker SE; Higginbotham ML
    Vet Comp Oncol; 2018 Mar; 16(1):E52-E60. PubMed ID: 28799187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic properties of toceranib phosphate (Palladia, SU11654), a novel tyrosine kinase inhibitor, in laboratory dogs and dogs with mast cell tumors.
    Yancey MF; Merritt DA; Lesman SP; Boucher JF; Michels GM
    J Vet Pharmacol Ther; 2010 Apr; 33(2):162-71. PubMed ID: 20444041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision.
    London CA; Malpas PB; Wood-Follis SL; Boucher JF; Rusk AW; Rosenberg MP; Henry CJ; Mitchener KL; Klein MK; Hintermeister JG; Bergman PJ; Couto GC; Mauldin GN; Michels GM
    Clin Cancer Res; 2009 Jun; 15(11):3856-65. PubMed ID: 19470739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety evaluation of combination vinblastine and toceranib phosphate (Palladia®) in dogs: a phase I dose-finding study.
    Robat C; London C; Bunting L; McCartan L; Stingle N; Selting K; Kurzman I; Vail DM
    Vet Comp Oncol; 2012 Sep; 10(3):174-83. PubMed ID: 22235914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety evaluation of combination CCNU and continuous toceranib phosphate (Palladia(®) ) in tumour-bearing dogs: a phase I dose-finding study.
    Pan X; Tsimbas K; Kurzman ID; Vail DM
    Vet Comp Oncol; 2016 Jun; 14(2):202-9. PubMed ID: 24735385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the adverse event profile and pharmacodynamics of toceranib phosphate administered to dogs with solid tumors at doses below the maximum tolerated dose.
    Bernabe LF; Portela R; Nguyen S; Kisseberth WC; Pennell M; Yancey MF; London CA
    BMC Vet Res; 2013 Sep; 9():190. PubMed ID: 24079884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of toceranib, piroxicam and thalidomide with or without hypofractionated radiation therapy on clinical outcome in dogs with inflammatory mammary carcinoma.
    Rossi F; Sabattini S; Vascellari M; Marconato L
    Vet Comp Oncol; 2018 Dec; 16(4):497-504. PubMed ID: 29806156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A retrospective study of proteinuria in dogs receiving toceranib phosphate.
    Piscoya SL; Hume KR; Balkman CE
    Can Vet J; 2018 Jun; 59(6):611-616. PubMed ID: 29910474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preliminary evaluation of serial (18) FDG-PET/CT to assess response to toceranib phosphate therapy in canine cancer.
    Leblanc AK; Miller AN; Galyon GD; Moyers TD; Long MJ; Stuckey AC; Wall JS; Morandi F
    Vet Radiol Ultrasound; 2012; 53(3):348-57. PubMed ID: 22360684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Toceranib Phosphate on Systolic Blood Pressure and Proteinuria in Dogs.
    Tjostheim SS; Stepien RL; Markovic LE; Stein TJ
    J Vet Intern Med; 2016 Jul; 30(4):951-7. PubMed ID: 27149912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retrospective evaluation of canine heart base tumours treated with toceranib phosphate (Palladia): 2011-2018.
    Lew FH; McQuown B; Borrego J; Cunningham S; Burgess KE
    Vet Comp Oncol; 2019 Dec; 17(4):465-471. PubMed ID: 31069932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Toceranib/Piroxicam/Cyclophosphamide Maintenance Therapy on Outcome of Dogs with Appendicular Osteosarcoma following Amputation and Carboplatin Chemotherapy: A Multi-Institutional Study.
    London CA; Gardner HL; Mathie T; Stingle N; Portela R; Pennell ML; Clifford CA; Rosenberg MP; Vail DM; Williams LE; Cronin KL; Wilson-Robles H; Borgatti A; Henry CJ; Bailey DB; Locke J; Northrup NC; Crawford-Jakubiak M; Gill VL; Klein MK; Ruslander DM; Thamm DH; Phillips B; Post G
    PLoS One; 2015; 10(4):e0124889. PubMed ID: 25923466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies.
    London CA; Hannah AL; Zadovoskaya R; Chien MB; Kollias-Baker C; Rosenberg M; Downing S; Post G; Boucher J; Shenoy N; Mendel DB; McMahon G; Cherrington JM
    Clin Cancer Res; 2003 Jul; 9(7):2755-68. PubMed ID: 12855656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and immunomodulatory effects of toceranib combined with low-dose cyclophosphamide in dogs with cancer.
    Mitchell L; Thamm DH; Biller BJ
    J Vet Intern Med; 2012; 26(2):355-62. PubMed ID: 22303814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrospective evaluation of toceranib phosphate (Palladia) use in cats with mast cell neoplasia.
    Berger EP; Johannes CM; Post GS; Rothchild G; Shiu KB; Wetzel S; Fox LE
    J Feline Med Surg; 2018 Feb; 20(2):95-102. PubMed ID: 29172873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination toceranib and lomustine shows frequent high grade toxicities when used for treatment of non-resectable or recurrent mast cell tumours in dogs: A European multicentre study.
    Bavcar S; de Vos J; Kessler M; de Fornel P; Buracco P; Murphy S; Hirschberger J; Argyle DJ
    Vet J; 2017 Jun; 224():1-6. PubMed ID: 28697868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pulse-Administered Toceranib Phosphate Plus Lomustine for Treatment of Unresectable Mast Cell Tumors in Dogs.
    Burton JH; Venable RO; Vail DM; Williams LE; Clifford CA; Axiak-Bechtel SM; Avery AC; Thamm DH
    J Vet Intern Med; 2015; 29(4):1098-104. PubMed ID: 26119008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.